Altimmune abandons ship on intranasal Covid-19 vaccine, refocusing on liver, obesity programs after trial flop

Kyle Blankenship

Among the also-rans in the Covid-19 vaccine race, small biotech Altimmune hoped to ride a novel intranasal formulation for its own candidate to market but …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Altimmune abandons ship on intranasal Covid-19 vaccine, refocusing on liver, obesity programs after trial flop

Kyle Blankenship

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Al­tim­mune aban­dons ship on in­tranasal Covid-19 vac­cine, re­fo­cus­ing on liv­er, obe­si­ty pro­grams af­ter tri­al flop

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Altimmune abandons ship on intranasal Covid-19 vaccine, refocusing on liver, obesity programs after trial flop